IPR Decision Disappointing for Coherus Biosciences (CHRS) But Focus Remains on Neulasta - Cowen
Cowen analyst Ken Cacciatore weighs in on Coherus Biosciences (NASDAQ: CHRS) following an adverse IPR decision on ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)